ScholarIQanswers from OpenAlex & ORCID
Kazuhiko Nakagawa
ResearcherPublications, citations & collaboration network
Kazuhiko Nakagawa is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kazuhiko Nakagawa have?
ScholarIQindexed works
Kazuhiko Nakagawa has 1,442 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kazuhiko Nakagawa have?
ScholarIQcitation count
Kazuhiko Nakagawa has 62,483 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kazuhiko Nakagawa?
ScholarIQh-index
Kazuhiko Nakagawa has an h-index of 103 in OpenAlex.
What is the i10-index of Kazuhiko Nakagawa?
ScholarIQi10-index
Kazuhiko Nakagawa has an i10-index of 556 in OpenAlex.
What is the ORCID of Kazuhiko Nakagawa?
ScholarIQorcid
The ORCID for Kazuhiko Nakagawa is on the source record.
What is the OpenAlex record for Kazuhiko Nakagawa?
ScholarIQopenalex
The OpenAlex for Kazuhiko Nakagawa is on the source record.
What are the most-cited papers on Kazuhiko Nakagawa?
ScholarIQmost cited works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose M. Pacheco, M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Jänne